ATE557039T1 - Neue a-galactosidasen - Google Patents

Neue a-galactosidasen

Info

Publication number
ATE557039T1
ATE557039T1 AT10165152T AT10165152T ATE557039T1 AT E557039 T1 ATE557039 T1 AT E557039T1 AT 10165152 T AT10165152 T AT 10165152T AT 10165152 T AT10165152 T AT 10165152T AT E557039 T1 ATE557039 T1 AT E557039T1
Authority
AT
Austria
Prior art keywords
group
erythrocytes
enzyme
immunodominant
galactosidases
Prior art date
Application number
AT10165152T
Other languages
English (en)
Inventor
Qiyong Peter Liu
Henrick Clausen
Original Assignee
Velico Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velico Medical Inc filed Critical Velico Medical Inc
Application granted granted Critical
Publication of ATE557039T1 publication Critical patent/ATE557039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1315—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/25—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from renal cells, from cells of the urinary tract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT10165152T 2005-10-31 2006-10-31 Neue a-galactosidasen ATE557039T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73184505P 2005-10-31 2005-10-31
US83600006P 2006-08-07 2006-08-07

Publications (1)

Publication Number Publication Date
ATE557039T1 true ATE557039T1 (de) 2012-05-15

Family

ID=38006440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10165152T ATE557039T1 (de) 2005-10-31 2006-10-31 Neue a-galactosidasen

Country Status (7)

Country Link
US (3) US7951552B2 (de)
EP (5) EP2502491B1 (de)
JP (4) JP5395436B2 (de)
AT (1) ATE557039T1 (de)
AU (3) AU2006308953B8 (de)
ES (4) ES2386413T3 (de)
WO (1) WO2007053565A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502491B1 (de) * 2005-10-31 2017-05-10 Velico Medical, Inc. Neue a-galactosidasen
CA2697999C (en) 2009-04-24 2013-04-30 Werner Hoelke A stabilized aqueous alpha-galactosidase composition and methods relating thereto
CN103349794B (zh) * 2013-05-08 2015-08-19 中国人民解放军军事医学科学院野战输血研究所 重组α-半乳糖苷酶清除异种皮肤抗原的方法和产品
US20150273111A1 (en) * 2014-04-01 2015-10-01 Lifecell Corporation Microbial enzymes for reduction of alpha-galactose from collagen based tissue
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN116732106A (zh) 2017-04-20 2023-09-12 E开创生物技术股份有限公司 产生基因修改的动物的方法
JP6789886B2 (ja) * 2017-06-09 2020-11-25 株式会社東芝 電子装置
CN117044707A (zh) * 2018-08-17 2023-11-14 不列颠哥伦比亚大学 用于供体器官上的碳水化合物抗原切割的酶促组合物、与其相关的方法和用途
TW202146648A (zh) * 2020-02-28 2021-12-16 美商克迪科思股份有限公司 人類α-半乳糖苷酶變異體
IL302830A (en) 2020-11-13 2023-07-01 Egenesis Inc Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant
CN116868059B (zh) * 2022-10-18 2024-04-05 天津德祥生物技术股份有限公司 血型抗原三糖偶联物在血型抗体检测中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427777A (en) 1980-08-14 1984-01-24 New York Blood Center, Inc. Enzymatic conversion of red cells for transfusion
US5606042A (en) 1994-09-08 1997-02-25 The Curators Of The University Of Missouri Glycine α-D-galactosidases
US5633130A (en) 1994-09-08 1997-05-27 The Curators Of The University Of Missouri Buffer system for increasing seroconversion efficiency
US5984858A (en) 1995-06-07 1999-11-16 Crosscart, Inc. Meniscal xenografts
US5865849A (en) 1995-06-07 1999-02-02 Crosscart, Inc. Meniscal heterografts
US6110206A (en) 1995-09-15 2000-08-29 Crosscart, Inc. Anterior cruciate ligament xenografts
US6184017B1 (en) 1996-05-08 2001-02-06 The Curators Of The University Of Missouri Glycine and phaseolus α-D-galactosidases
EP1059891A4 (de) 1998-03-06 2004-05-19 Crosscart Inc Xenotransplantate aus weichem gewebe
US6972041B1 (en) 1998-03-16 2005-12-06 Crosscart, Inc. Bone xenografts
US6383732B1 (en) 1999-02-11 2002-05-07 Crosscart, Inc. Method of preparing xenograft heart valves
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US6267786B1 (en) 1999-02-11 2001-07-31 Crosscart, Inc. Proteoglycan-reduced soft tissue xenografts
US7767415B2 (en) * 2001-09-25 2010-08-03 Velico Medical, Inc. Compositions and methods for modifying blood cell carbohydrates
US7064187B2 (en) 2002-11-26 2006-06-20 Crosscart, Inc. Substantially non-immunogenic injectable collagen
AU2004259019B2 (en) 2003-07-21 2010-09-23 Lifecell Corporation Acellular tissue matrices made from galactose alpha-1,3-galactose-deficient tissue
EP2502491B1 (de) * 2005-10-31 2017-05-10 Velico Medical, Inc. Neue a-galactosidasen

Also Published As

Publication number Publication date
US7951552B2 (en) 2011-05-31
EP2250884B1 (de) 2012-12-05
ES2661929T3 (es) 2018-04-04
AU2010202494A1 (en) 2010-07-08
US9034626B2 (en) 2015-05-19
US20150087061A1 (en) 2015-03-26
EP2250883A3 (de) 2011-03-09
EP1945269A2 (de) 2008-07-23
EP2250884A2 (de) 2010-11-17
JP5395436B2 (ja) 2014-01-22
US20090220474A1 (en) 2009-09-03
EP2250883B1 (de) 2012-05-09
EP2250885A2 (de) 2010-11-17
ES2386413T3 (es) 2012-08-20
JP2014132904A (ja) 2014-07-24
JP2009516504A (ja) 2009-04-23
EP2250885A3 (de) 2010-12-22
AU2010202494B2 (en) 2013-08-22
AU2006308953B2 (en) 2013-08-15
ES2400838T3 (es) 2013-04-12
AU2006308953A1 (en) 2007-05-10
JP5395747B2 (ja) 2014-01-22
AU2010202013B2 (en) 2013-08-15
JP2010268794A (ja) 2010-12-02
ES2637314T3 (es) 2017-10-11
EP2250883A2 (de) 2010-11-17
US8883478B2 (en) 2014-11-11
JP2010263895A (ja) 2010-11-25
AU2006308953B8 (en) 2013-12-05
AU2010202013A1 (en) 2010-06-10
EP1945269A4 (de) 2010-02-17
WO2007053565A2 (en) 2007-05-10
US20110014170A1 (en) 2011-01-20
WO2007053565A3 (en) 2009-05-07
EP2502491A2 (de) 2012-09-26
EP2250884A3 (de) 2011-03-09
EP2502491A3 (de) 2012-12-19
EP2502491B1 (de) 2017-05-10

Similar Documents

Publication Publication Date Title
EP1945269A4 (de) Neue a-galactosidasen
DE69827152D1 (de) Chemilumineszierende zusammensetzungen und entsprechende verfahren
WO2003023021A3 (de) Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
ATE456678T1 (de) Nukleinsäurenachweisverfahren mit erhöhter empfindlichkeit
ATE470857T1 (de) Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
NO20080887L (no) Fremgangsmate for detektering ved pavisning av mikroorganismer samt sett for detektering ved pavisning av mikroorganismer
ATE536550T1 (de) Halbleiter nanokristalle enthaltende transfektibare mizellen
DE602007006471D1 (de) Nachweisverfahren für grippeviren
MX2010000031A (es) Deteccion mejorada de microorganismos.
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
DK1290155T3 (da) Nukleinsyreisolering
WO2007022401A3 (en) Method and language for process expression
AU4857700A (en) Method for rapidly detecting and enumerating microorganisms in mammalian cell preparations using atp bioluminescence
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
EP1749854A4 (de) Polysaccharid/kohlenstoffnanoröhre-verbund
SG171630A1 (en) Protein detection reagents and methods with dyes and dextrins
ATE517343T1 (de) Bestimmung von konzentrationsänderungen
NO20083933L (no) Flermodus manipulatorarm og drivsystem
WO2003027245B1 (en) CONVERSION OF RED BLOOD CELLS A, B, AND AB USING a-N-ACETYLGALACTOSAMINIDASES AND a-GALACTOSIDASE
BRPI0415884A (pt) imobilização de biocatalizador
ATE530657T1 (de) Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
DE60314302D1 (de) Messzelle
EP2502492A3 (de) Neue a-galactosidasen
WO2001094627A3 (en) Assay techniques based on growth stage dependent expression in c. elegans